Medvivo, a UK-based health and care services provider has acquired Expert 24, a global developer of clinical decision support applications for some of the world’s largest healthcare providers, insurers and health information platforms including BUPA, AXA PPP Healthcare, U.S. Department of Veterans Affairs and WebMD.
The acquisition strengthens Medvivo’s range of clinical technology products and services built up over the past 11 years; and will support Expert 24’s continued growth throughout the US, UK and Europe. The expansion will also provide job opportunities for UK-based developers seeking to pursue careers in creating cutting-edge digital solutions that improve essential health-care services.
Founded in 2001, with operations in the UK and United States, Expert 24 provides customized, trusted algorithms for some of the world’s largest healthcare providers, insurers and health information platforms including BUPA, AXA PPP Healthcare, U.S. Department of Veterans Affairs and WebMD. Expert 24’s proprietary technology refines and integrates the most complex clinical algorithms and assessments to help its clients tackle acute and primary care challenges, and manage chronic conditions. Its population health and personal health risk management product helps providers to assess and better understand macro health risks as well as providing insights that can encourage individuals to change behaviors towards managing their health and well-being.
“Effective, patient-centric healthcare services rely on innovations that unlock efficiencies and plug skills shortages while empowering the people that use them. To help meet this need, Medvivo is working to become the UK’s number one provider of digital healthcare products and services. Bringing such a successful and complementary operation as Expert 24 into our stable will deepen our offering, extend our reach internationally, and strengthen our ambition to improve the accessibility, quality, and cost-effectiveness of healthcare services,” said Andrew Gardner, CEO of Medvivo.
Financial terms of the acquisition were not disclosed.
